BioNTech Outlines 2025 Strategy at J.P. Morgan Conference

TL;DR

BioNTech laid out its 2025 game plan at JPM conference, focusing on pipeline and growth.

AI Summary

On January 14, 2025, BioNTech SE presented its 2025 strategic priorities at the 43rd annual J.P. Morgan Healthcare Conference. The company, headquartered in Mainz, Germany, is focused on advancing its pipeline and expanding its commercial footprint.

Why It Matters

This filing provides insight into BioNTech's forward-looking plans, which could impact its future product development and market position in the biotechnology sector.

Risk Assessment

Risk Level: low — The filing is a routine corporate update and does not contain significant new financial information or material adverse events.

Key Players & Entities

• BioNTech SE (company) — Registrant
• January 14, 2025 (date) — Date of presentation
• J.P. Morgan Healthcare Conference (event) — Conference where priorities were presented
• Mainz, Germany (location) — Company headquarters

FAQ

From the Filing

0001776985-25-000002.txt : 20250114 0001776985-25-000002.hdr.sgml : 20250114 20250114065845 ACCESSION NUMBER: 0001776985-25-000002 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 36 CONFORMED PERIOD OF REPORT: 20250114 FILED AS OF DATE: 20250114 DATE AS OF CHANGE: 20250114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 25527731 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kjpmpresentationpr14.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JANUARY 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On January 14, 2025, BioNTech SE outlined its 2025 strategic priorities at the 43rd annual J.P. Morgan Healthcare Conference. The press release and presentation are attached as Exhibits 99.1 and 99.2, respectively. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Jens Holstein By: /s/ Dr. Sierk Poetting Name: Jens Holstein Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: January 14, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech provides business and pipeline updates at 43rd annual J.P. Morgan Healthcare Conference 99.2 Presentation EX-99.1 2 a99_1bntxjpmorganhealthcar.htm EX-99.1 Document Exhibit 99.1 BioNTech provides business and pipeline updates at 43rd annual J.P. Morgan Healthcare Conference • Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches • BioNTech aims to develop BNT327/PM8002 as a next-generation immuno-oncology (“IO”) backbone for the Company’s combination strategy targeting a broad range of indications • Progressing development of BNT327/PM8002 with initiation of global clinical trials with registrational potential in first-line small cell lung cancer (“SCLC”) and non-small cell lung cancer (“NSCLC”) • Advancing BNT327/PM8002 combination strategy with initiation of a second antibody drug conjugate (“ADC”) combination trial&#59; additional ADC-combination trials planned to be initiated in 2025 • Progress in mRNA cancer immunotherapy portfolio with multiple randomized trial read-outs of personalized and off-the-shelf candidates expected in 2025 and 2026 MAINZ, Germany, January 14, 2025 (GLOBE NEWSWIRE)  -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today will present its 2025 strategic priorities and p